Matuskova Hana, Porschen Lisa T, Matthes Frank, Lindgren Arne G, Petzold Gabor C, Meissner Anja
Department of Experimental Medical Sciences, Lund University, 221 84 Lund, Sweden.
Wallenberg Centre for Molecular Medicine, Lund University, 221 84 Lund, Sweden.
iScience. 2024 May 20;27(6):110031. doi: 10.1016/j.isci.2024.110031. eCollection 2024 Jun 21.
Sphingosine-1-phosphate receptors (S1PRs) are promising therapeutic targets in cardiovascular disease, including ischemic stroke. However, important spatiotemporal information for alterations of S1PR expression is lacking. Here, we investigated the role of S1PR3 in ischemic stroke in rodent models and patient samples. We show that S1PR3 is acutely upregulated in perilesional reactive astrocytes after stroke, and that stroke volume and behavioral deficits are improved in mice lacking S1PR3. Further, we find that administration of an S1PR3 antagonist at 4-h post-stroke, but not at later timepoints, improves stroke outcome. Lastly, we observed higher plasma S1PR3 concentrations in experimental stroke and in patients with ischemic stroke. Together, our results establish S1PR3 as a potential drug target and biomarker in ischemic stroke.
鞘氨醇-1-磷酸受体(S1PRs)是心血管疾病(包括缺血性中风)中很有前景的治疗靶点。然而,目前缺乏关于S1PR表达改变的重要时空信息。在此,我们研究了S1PR3在啮齿动物模型和患者样本的缺血性中风中的作用。我们发现,中风后病灶周围反应性星形胶质细胞中S1PR3会急性上调,并且在缺乏S1PR3的小鼠中,脑梗死体积和行为缺陷有所改善。此外,我们发现中风后4小时给予S1PR3拮抗剂可改善中风预后,但在更晚的时间点给予则无效。最后,我们观察到实验性中风和缺血性中风患者的血浆S1PR3浓度较高。总之,我们的研究结果表明S1PR3是缺血性中风的潜在药物靶点和生物标志物。